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Polyclonal Antibodies to Quantitate Cis-
Diamminedichioroplatinum(ll) DNA
Adducts in Cancer Patients and Animal
Models
by Miriam C. Poirier,* Eddie Reed,* Leonard A. Zwelling,*
Robert F. Ozols,* Charles L. Litterst,* and Stuart H. Yuspa*
cis-Diamminedichloroplatinum (II) (cis-DDP), the antitumor drug, is cytotoxic in vitro primarily by bind-
ingtoDNAanddisrupting its normalfunctions. Wehave studied cis-DDP modification ofDNAin nucleated
peripheral blood cells (buffy coat cells) oftesticular and ovarian cancer patients receiving cis-DDP chem-
otherapy, andofuntreatedcontrols. Usingahighlysensitiveenzyme-linked immunosorbentassay(ELISA)
with an antiserum specific for the bidentate intrastrand N7-deoxyguanosine adduct, blood cell DNA was
assayed at multiple times during courses ofcis-DDP treatment. A total of 138 samples were analyzed from
54 individuals. Ofthese, all samples from 18 untreated controls were negative, while 44 out of 120 samples
from cis-DDP patients were positive. Testicular and ovarian cancer patients receiving chemotherapy on
the first course, and given cis-DDP in 21- or 28-day cycles (five days of drug infusion followed by two or
threedrug-freeweeks)accumulatedcis-DDP-DNAadducts inbloodcell DNAasafunction ofdose. Patients
receiving their first course ofcis-DDP on 56-day cycles and those given high doses ofthis drug after failing
other chemotherapy showed much slower adduct accumulation than patients receiving their first course
on 21- or 28-day cycles. Adduct accumulation, in positive patients, occurred both as a function of total
cumulative dose and with increasing cycle number, suggesting that adduct removal took at least a month
in these patients. Disease response data, available on 33 of the 45 cis-DDP patients, suggested that indi-
viduals who failed cis-DDP chemotherapy were less likely to form measurable cis-DDP-DNA adducts than
those who responded. Characteristics ofcis-DDP-DNA adduct formation and removal in rat tissues have
indicated that both the dose-response phenomenon and slow adduct removal occur in rats exposed to cis-
DDP. It is anticipated that studies with patients and animal models will lead to a greater understanding
ofthe mechanisms underlying cis-DDP tumoricidal activity and may lead to more effective and less toxic
drug treatment methods.
Introduction
cis-Diamminedichloroplatinum (II) (cis-DDP) is one
ofthe most effective tumoricidal drugs currently avail-
able. In combination with other drugs, it is responsible
for cure rates of approximately 80% in testicular car-
cinoma(1)andresultsinclinicalcomplete response rates
of approximately 65% in advanced ovarian cancer pa-
tients (2). Although the mechanism of therapeutic ef-
ficacy is not completely understood, the cytocidal activity
of cis-DDP has long been associated with effects on
DNA (3-5), and damage in the form ofspecific adducts
has been characterized chemically (6-8). This includes
primarily mono-adducts on deoxyguanosine (dG), in-
trastrand adducts between two dGs with or without an
intervening base, and interstrand DNA-DNA cross-
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links. Thus, it appeared possible that adducts might
form in cancer patients treated with cis-DDP, and that
determination of such cis-DDP-DNA adducts might
provide a useful model in which to investigate the bi-
ological consequences of adduct formation in humans.
Such a study would be attractive for a variety of rea-
sons: drugdosages and exposure times would be known
precisely, the DNA ofperipheralblood would be readily
obtainable, measurableadductscouldbe correlatedwith
clinical course and the ensuing information might assist
the clinician in management of the neoplastic disease.
In addition, since secondary tumors may eventually oc-
cur among the individuals currently undergoing cis-DDP-
induced cures, such data might be useful in exploring
the role of DNA adduct formation during human
tumorigenesis.
Recently, the utilization ofantibodies specific for car-
cinogen-DNA adducts has made possible the develop-
ment of sensitive immunoassays able to detect a fewPOIRIER ET AL.
hundred adducts per mammalian genome, or about one
adduct in 108 nucleotides (9). The highly sensitive and
specific nature ofthis technology, coupled with the lack
of a requirement for a radioactive sample, has made it
an attractive candidate for attempting to monitor DNA
adducts in the human population. A major adduct formed
in vivo subsequent to the interaction between cis-DDP
and DNAis anintrastrand bidentate adduct on adjacent
deoxyguanosines [Eq. (1)], where linkage is through N7
positions by displacement of the cis-chlorides (d[GpG]-
N7-diammnineplatinum) (7). An antiserum elicited against
NH3 NH3
\ / + dX-p-dG-p-dG-p-dX
Pt
DNA
cis-DDP
NH3 NH3
Pt
dX-p-dG-p-dG-p-dX
Bidentate Intrastrand N7 Adduct (1)
calf-thymus DNA modified with cis-DDP in vitro (4.4
adducts per 100 nucleotides) has been shown to have
specificity directed primarily towards this intrastrand
bidentate adduct and to recognize DNAs from cultured
cells and tissues of intact animals exposed to cis-DDP
(10,11). The present study demonstrates that the in-
trastrand bidentate adduct is present in the DNA of
nucleated peripheral blood cells ofcancerpatients given
cis-DDP chemotherapy, and in tissues of rats to cis-
DDP by intravenous injections.
Methods
cis-DDP Administration to Patients and
Rodents
Individuals studied were being treated for either
ovarian or testicular cancer by the Medicine Branch of
the National Cancer Institute. These patients were given
cis-DDP therapy as part ofapproved experimental pro-
tocols (see Table 1). cis-DDP dose varied with protocol
and was between 10 mg/m2/day x 5 and 40 mg/m2/day
x 5. Control groups were untreated normal volunteers
andpatients onnonplatinumcombination chemotherapy
for non-Hodgkin's lymphoma. In addition some of the
patients were studied for adducts prior to receiving any
cis-DDP or other chemotherapy and therefore served
as their own controls.
cis-DDP chemotherapy was given in courses com-
prised ofthree to five cycles. In each cycle the drugwas
administered as a 30-min daily intravenous infusion on
each offive consecutive days, and no cis-DDP was given
fortheremainderofthe cycle. Onthe morningfollowing
and infusion, 35 to 50 mL of blood was obtained via
venipuncture, centrifuged (20 min, 5000g, 40C), and the
nucleated cells (the buffy coat) were aspirated and fro-
zen at -200C until DNA isolation.
Female Sprague-Dawley rats weighing 175-200 gwere
housed five to a cage in clear plastic cages with hard-
wood bedding and given free access to Purina Lab chow
and tap water ad libitum. cis-DDP intravenous (IV)
injections of 6 or 30 mg/kg were given at 0.9% NaCl,
at a 1 mg/mL solution concentration, within 30 min of
preparation. Injections were given to animals under light
ether anesthesia, and sacrifice was with ether overdose
4 hr after injection. Kidneys were excised and frozen
at -20°C until DNA isolation.
DNA Preparation and ELISA
DNA was extracted from buffy coat cells and rat kid-
neys by CsCl gradient centrifugation (12) within 1 month
of the time the sample was taken. This DNA was di-
alyzed against water and quantitated by absorbance at
260 nm. Samples were assayed for cis-DDP-DNA ad-
ducts by ELISA as previously reported (10,11) with
modifications. Poly(vinyl chloride) U-bottom microtiter
plate wells (Dynatech, Inc., Alexandria, VA) were coated
sequentially with DEAE-dextran and 0.5ngofcalfthy-
mus DNA, either unmodified or modified to 4.3 % with
cis-DDP. In separate tubes, rabbit antiserum specific
for cis-DDP-DNA (diluted 1:60,000) was reacted with
standard or sample DNAs for 30 min at 37°C. Subse-
quently, the mixture was added to the microtiter plates
so that remaining free antibody could bind cis-DDP-
DNA coated on the wells. After 90 min of further in-
cubation, unbound antigen-antibody complexes were
removed by three washes with PBS-Tween. Excess al-
kaline phosphatase conjugate (goat-anti-rabbit-IgG,
Sigma, Inc., St. Louis, MO) was then added tothe wells
and incubated 90 min to interact with the bound anti-
cis-DDP-DNA antiserum. Afterwashingagain, excess
p-nitrophenyl phosphate in 1 M diethanolamine buffer,
pH 8.6, was added to each well, and the extent of hy-
drolysis to p-nitrophenol was proportional to the quan-
tityofbound anti-cis-DDP-DNA. ATitertekMultiskan
colorimetric microtiter plate reader was used at 405 nm
to determinep-nitrophenol. The ELISA standard curve
50% inhibition, under the assay conditions described,
was at 10 + 4 fmole (mean + range) ofplatinum (atomic
absorption spectroscopy performed by S.J. Lippard) in
standard immunogen cis-DDP-DNA. DNA samples
were assayed asnative, with 30 to 35 ,ugofsample DNA
per well and 35 jig of unmodified calf thymus DNA in
the standard curve wells. Each unknown DNA sample
was assayed two or three times by ELISA and not
scored as positive unless it produced greater than 20%
inhibition in the assay.
Data Analysis
Adduct analyses were performed on 138 samples col-
lected from a total of 53 individuals. Patients in the
treatment groups outlined above were studied one or
more times during their course of chemotherapy. In-
dividuals in the control groups were generally studied
only once. Linear regression analyses of data points in
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Table 1. Summary of ELISA data from 138 human peripheral blood DNA samples.
Drug Blood samples
Chemotherapy cycle time, Number of
Type of cancer protocol days individuals Positive Negative
Testicular cis-DDP, combination ia 21 or 28 11 11 23
Ovarian cis-DDP, combination 20 28 13 11 16
Ovarian cis-DDP, combination 3a 56 8 8 12
Ovarian cis-DDP, single high dose 28 13 14 25
None None 4 0 4
Non-Hodgkin's
lymphoma Non-cis-DDP 4 0 4
Ovarian or
testicular None (prior to cis-DDP) - 10 0 10
'Combination 1 is cis-DDP, velban, bleomycin, with orwithout epidophyllotoxin; combination2 is cytoxan, cis-DDP; combination 3 is cytoxan,
hexamethylmelamine, irradiation, cis-DDP with or without radiosensitizer.
each patient group were performed by computer. Sta-
tistical significance was calculated by the two-sided
Fisher Exact Test as described by Armitage (13).
Results
Antibody Specificity and Assay Sensitivity
Theantiserumutilized inthese studies has previously
been shown to be specific for adducts of cis- but not
trans-DDP-DNA formed in cultured cells and intact
animals (10). This antiserum fails to recognize cis-DDP
alone (Fig. 1A), DNA alone (Fig. 1B), and the DNA
interstrand crosslinks determined by alkaline elution
(5). Through the use of a highly sensitive competitive
ELISA (Fig. 1A) to which 50 ,ug samples of DNA can
be added permicrotiterplate well, it is possible to mea-
sure attomole (10-0' mole) quantities of cis-DDP-DNA
adduct per microgram ofDNA. A series ofstudies with
homopolymers and heteropolymers modified with cis-
DDP, and calf-thymus DNAs modified with various
platinum drug analogs have indicated that the antibody
specificity is directed towards d(GpG)-N7-diamminepla-
tinum, a bidentate adduct with cis covalent bonds on
the same strand of DNA (11).
Assay of cis-DDP-DNA Adducts in
Nucleated Peripheral Blood Cells of
Cancer Patients
ELISA assay proffles, showing competition for spe-
cific antibody by increasing amounts ofbuffy coat DNA
from a normal volunteer and an ovarian cancer patient
receiving40mg/m2/dayofcis-DDP, areshowninFigure
1B. It is evident that the antibody recognized the pa-
tient DNAand notthe DNAfromthe normalvolunteer.
This constituted the first evidence that measurable lev-
els ofcis-DDP-DNA intrastrand adducts are formed in
individuals receiving cis-DDP chemotherapy. The an-
tibody recognition is not as complete as with the im-
munogen cis-DDP-DNA since the slope of the
competition curve (Fig. 1B) is more shallow than the
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FIGURE 1. Plots of(A) representative ofELISA standard curveand
(B) ELISA of patient buffy coat cell DNA. (A) Mixtures of anti-
cis-DDP-DNA (diluted 1:30,000) andeitherimmunogencis-DDP-
DNA (4.3% modified) (0), or cis-DDP (0) were assayed in com-
petition with 0.5 ng of cis-DDP-DNA (modified 4.3%) coated to
microtiter wells under conditions described in Methods. (B) DNA
extracted from buffy coat cells ofeither an ovarian cancer patient
on cis-DDP therapy (-) or a normal volunteer (0) was mixed with
anti-cis-DDP-DNA (diluted 1:60,000) and assayed in competition
as above. Increasing quantities of DNA (,ug) are plotted on the
abscissa.
standard curve (Fig. 1A). This observation suggests
that other types of cis-DDP-DNA adducts (possibly
mono-orG-X-Gadducts)maybeformedsimultaneously,
resulting in lower affinity antibody binding for certain
DNA regions and an overall decrease in ability to com-
pete, as compared to the immunogen DNA.
Table 1 shows a summaryofthe results fromELISAs
of138blood DNAsamples obtained from54individuals.
Most patients were studied during more than one cycle
ofchemotherapy, and mostsamples were obtained after
the 5-day drug infusion (the morning of day 6). This
time was chosen because early results demonstrated
that the proportion of positive samples increased to-
wards the end ofthe infusion. Table 1 shows that blood
samples from all 18 individuals who did not receive cis-
DDP therapy were negative. In addition, 44 samples
out of 120 from cis-DDP-treated individuals were pos-
itive in the assay. The first three groups of cancer pa-
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FIGURE 2. Positive cis-DDP-DNA adduct determination on buffy
coat DNA samples from patients on their first course of 21- and
28-day cycle chemotherapy. Adduct levels (ordinate) are ex-
pressed as afunction of(A) cis-DDP cumulative dose and (B) cycle
of treatment. Both plots are of the same data. S = slope, I =
intercept, CC = correlation coefficient, are from linear regression
analysis (lines not drawn).
tients shown in Table 1 were individuals who received
no courses of chemotherapy prior to this study. The
fourth group comprised more advanced individuals who
had previously failed various courses of cis-DDP and/
or other therapy. An analysis of the ELISA data by
group showed that some of the testicular and ovarian
patients (combinations 1 and 2, Table 1) who were given
cis-DDPin21-and28-daycyclesand werefollowed from
the inception of chemotherapy, accumulated cis-DDP-
DNAadducts withincreasingcumulative doseand cycle
number. Data for the positive samples are plotted in
Figure 2, and linear regression parameters (noted on
the chart) indicate good linear fit. In contrast, individ-
uals receiving their first course ofchemotherapy on 56-
day cycles (Table 1, combination 3) appeared not to
accumulate adducts as well as those in the previous
groups (data not shown, correlation coefficient = 0.48).
Taken together, these data suggest that a substantial
portion ofthe adducts formed as the result of one cycle
of treatment are removed during 56 days, with a half-
life for removal in the range of 28 days. The fourth
patient group, individuals on "salvage" high-dose cis-
DDP, did not accumulate adducts in a similarconsistent
fashion (data not shown, correlation coefficient = 0.63),
suggesting that the combination of advanced disease
andpreviouschemotherapy maysomehowaltertheabil-
ity of the patient to form or remove measurable cis-
DDP-DNA adducts.
Theabilitytodetect cis-DDP-DNAadductformation
in patients provides an opportunity to correlate adduct
formation with a biological end point, which is in this
case the response to therapy. From the computerized
patient records it was possible to gather disease re-
sponse data on 33 of the cis-DDP-exposed patients. Of
these, 12 were given cis-DDP as a single agent and 21
received combination chemotherapy. The results are
showninTable2andsuggestthat amongtheindividuals
who did not form cis-DDP-DNA adducts there were
fewer partial or complete remissions as compared to
those who did form adducts (p = 0.048 by Fischer's
Exact two-sided test). Since both the responding and
nonresponding groups received essentially the same
amount ofcis-DDP, the formation ofmeasurable quan-
tities of adduct appears to correlate positively with a
response to therapy. This type of analysis will become
more definitive as data become available for all of the
individuals under study.
Quantitation of cis-DDP-DNA Adduct
Formation in Rat Tissues by ELISA
In anattempttoelucidatemechanismsunderlyingcis-
DDP therapeutic efficacy in cancer patients, experi-
ments were begunin animalmodels. Kidney was chosen
as the tissue to monitor in these studies since it is a
known target for cis-DDP toxicity. Although we do not
yet have extensive animal data, the results available
show certain distinct parallels within the human study.
Table 3 shows data from two experiments in which we
have investigated cis-DDP-DNA adduct formation with
increasing cis-DDP dose, and persistence ofthe adduct
after drug exposure, in kidney tissue offemale rats. In
experiment A (Table 3) the higher adduct levels were
clearly a result of higher dose. One should note how-
ever, that 30 mg/kg is acutely toxic and animals do not
survive for morethan afewdays. Therefore, when mon-
itoring the time course of adduct removal (experiment
B, Table 3) the lower dose of 6 mg/kg was chosen. Ex-
periment B shows that little or no adduct was removed
during 2 weeks subsequent to a single dose ofcis-DDP.
Therefore cis-DDP-DNA adducts persist in rat kidney
for prolonged periods showing a distinct parallel to the
results of the human studies.
Discussion
The ability to quantitate DNA adducts ofcis-DDP in
nucleated peripheral blood cells of cancer patients has
been achieved through the use of a highly sensitive im-
munoassay and an antiserum with primary specificity
directed towards the d(GpG)-N7-diammineplatinum in-
trastrand adduct. The data show that many individuals
given cis-DDP for the first time on 21- or 28-day cycles
accumulated DNA adducts with cycle and dose. Accu-
mulation is less clear in patients on 56-day cycles, sug-
gesting that removal of this adduct or loss of adduct-
containing cells may take place within a 2-month time
period. These human results, however, have been ob-
tained in circulating cells, and studies on solid tissues
or tumors remain to be done. The data also show an
apparent positive correlation between the formation of
measurable adduct levels and disease response to cis-
DDP treatment, althoughthisrelationship requires fur-
therinvestigation. Since there is ahigh probability that
we are not measuring the only adduct formed, the pos-
sibility exists that other adducts may be contributing
to the observed biological end point, that is disease
response.
A B
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Table 2. Disease response in all patients grouped by treatment and by adduct status.
Cumulative
cis-DDP
Percent with dose
Number of partial or complete (mean + SD),
Treatment ELISA status patients remission mg/m2
Single agent
A 12
Never pos 4 0 (0/4) 756± 445
Pos a once 8 50% (4/8) 877 395
Combination
B 21
Never pos 6 50%(3/6) 543 ±184
Posa once 15 87%(13/15) 575 ±219
A +B 33
Never pos 10 30%(3/10)
Pos > once 23 74%(17/23)
Table 3. cis-DDP-DNA adduct levels in kidneys of female rats
exposed IV to cis-DDP.a
cis-DDP Time of sac- cis-DDP-DNA adducts,
dose, mg/kg rifice, hr atmole/,ug DNA
Expt. A 6 6hr 130 ± 30
30 6hr 542 ± 28
Expt. B 6 6hr 309 ± 35
6 7days 357 ± 31
6 13days 300 ± 14
aAnimals were injected intravenously with either 6 or 30 mg/kg
cis-DDP and eithersacrificed 6hrlaterormaintained foranadditional
7 or 13 days. Values represent tissues from two orthree rats assayed
two or three times by ELISA (mean ± range).
Studies with animal models reported here show in-
terestingparallels withthehumandata. Ratkidneywas
chosen as the most relevant tissue because of the sig-
nificant kidney toxicity noted in patients and animal
models. Attempts to measure adducts in rat blood were
not successful because of the small yield of DNA. In
performingthe studiesreportedherewe observed large
interanimal variability in cis-DDP-DNA adduct for-
mation among inbred animals in the same group. This
variability may be related to feeding cycles since over-
night fasting has reduced the variability in subsequent
experiments (datanot shown). Itis clear, however, that
cis-DDP-DNA adducts are formed in rat kidney in a
dose-dependent fashion, and that these adducts are
highly persistent, since little or no removal took place
within the first 2 weeks after exposure. These studies
are being extended to include rats bearing the Walker
256 sarcoma and nude mice carrying cis-DDP sensitive
and resistent human ovarian tumors. In tumor-bearing
animal models it may be possible to determine whether
or not specific adduct levels are associated with anti-
tumorigenic efficacy in both kidney and neoplasm, and
if manipulation of drug administration may modulate
adduct formation in tumor tissues.
Ofthe many possible sequelae cis-DDP may produce
in humans, one of the most ominous is the generation
of second malignancies, reports ofwhich have been re-
centlypublished (14,15). Itispossible thatthe slowrate
ofintrastrand adduct removal contributes to the chem-
otherapeutic potency of cis-DDP and also that this ad-
duct persistency may be related to the possible
development of treatment-induced neoplasia. Adduct
persistence is known to be associated with tumorige-
nesis in animal models. For example, in neonatal rats
exposed to ethylnitrosourea, a neurooncogenic effect in
brain tissue has been shown to correlate directly with
the slowrate ofrepairofthe 06-ethyl-dG adduct formed
by ethylnitrosourea (16). If reports of cis-DDP-related
neoplasia become more frequent, a difficult therapeutic
dilemma may ensue, and data generated in studies such
as ours may be useful in determining if adduct accu-
mulation is associated with risk of second malignancy.
It is hoped that the ability to monitor cis-DDP-DNA
adducts may allow the clinician to titrate cis-DDP for
chemotherapeutic potency while minimizing immediate
toxicity and the potential threat of second malignancy.
Studies utilizing the ELISA to quantitate adducts in
animal models may become a useful adjunct for design-
ing drug treatment protocols and for elucidating mech-
anisms underlying drug efficacy.
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